Community Contributor
Member since 2023
Views
2.1k Total number of views
Fair Values Set
55 Total number of fair values set
Comments
3 Total number of comments
Followers
2 Total number of followers

No bio added yet

No link added
US$320.94
14.3% undervalued intrinsic discount
Fair Value
Revenue
6.24% p.a.
Profit Margin
27.27%
Future PE
10.09x
Price in 2031
US$451.52
CHF 430.01
25.0% undervalued intrinsic discount
Fair Value
Revenue
6.77% p.a.
Profit Margin
20.33%
Future PE
23.15x
Price in 2031
CHF 0
€33.8
85.4% undervalued intrinsic discount
Fair Value
Profit Margin
13.86%
Future PE
18.06x
Price in 2029
€47.88
ELTX logo
Elicio Therapeutics

Very Bullish

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more

View narrative
US$100
89.4% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2031
US$140.1
US$400
1.0% undervalued intrinsic discount
Fair Value
Revenue
76.64% p.a.
Profit Margin
42.92%
Future PE
20.43x
Price in 2031
US$668.61
US$95
55.6% undervalued intrinsic discount
Fair Value
Revenue
19.46% p.a.
Profit Margin
32%
Future PE
15x
Price in 2031
US$129.6
US$268.64
59.0% undervalued intrinsic discount
Fair Value
Revenue
18.36% p.a.
Profit Margin
40.03%
Future PE
21.75x
Price in 2030
US$378.98
US$386.43
0.4% undervalued intrinsic discount
Fair Value
Revenue
11.73% p.a.
Profit Margin
32.23%
Future PE
30.45x
Price in 2030
US$574.32